Effects of Statin Use for Primary Prevention among Adults Aged 75 Years and Older in the National Health Insurance Service Senior Cohort (2002-015)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Sunyoung | - |
dc.contributor.author | Choi, Hangseok | - |
dc.contributor.author | Won, Chang Won | - |
dc.date.accessioned | 2023-03-08T14:03:44Z | - |
dc.date.available | 2023-03-08T14:03:44Z | - |
dc.date.issued | 2020-06 | - |
dc.identifier.issn | 2508-4909 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/63408 | - |
dc.description.abstract | Background: This study aimed to identify adverse events and mortality in adults aged 75 years and older who were initially prescribed statins for primary prevention. Methods: This retrospective study analyzed the data from the National Health Insurance Corporation-Senior Cohort from 2002 to 2015. An exact block matched model was constructed from statin user and statin non-user groups. Results: The study sample comprised 1,370 older adults (mean age, 78 years), with 685 statin non-users matched to 685 new statin users. Compared to non-users, the adjusted hazard ratios (HRs) of new statin users were 0.83 (p=0.04) for all-cause mortality, 1.24 (p=0.003) for major adverse cardiovascular events, and 1.18 (p=0.06) for new-onset diabetes mellitus. In a sub-analysis of statin use duration, longer statin use (>5 years) was associated with a significantly lower risk of all-cause mortality (HR=0.76, p=0.01) but not with major adverse cardiovascular events (HR=0.88, p=0.36) or new-onset diabetes mellitus (HR=0.95, p=0.78) after adjusting for age, sex, body mass index, diabetes mellitus, hypertension, aspirin use, and antiplatelet use. Conclusion: Our findings suggested that statins started for primary prevention in older adults aged 75 years and older had an advantageous effect on all-cause mortality only if used for at least 5 years. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN GERIATRIC SOC | - |
dc.title | Effects of Statin Use for Primary Prevention among Adults Aged 75 Years and Older in the National Health Insurance Service Senior Cohort (2002-015) | - |
dc.type | Article | - |
dc.identifier.doi | 10.4235/agmr.20.0028 | - |
dc.identifier.bibliographicCitation | ANNALS OF GERIATRIC MEDICINE AND RESEARCH, v.24, no.2, pp 91 - 98 | - |
dc.identifier.kciid | ART002599676 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000546282300005 | - |
dc.identifier.scopusid | 2-s2.0-85088577750 | - |
dc.citation.endPage | 98 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 91 | - |
dc.citation.title | ANNALS OF GERIATRIC MEDICINE AND RESEARCH | - |
dc.citation.volume | 24 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Aged | - |
dc.subject.keywordAuthor | Cardiovascular disease | - |
dc.subject.keywordAuthor | Hydroxymethylglutaryl-CoA reductase inhibitors | - |
dc.subject.keywordAuthor | Mortality | - |
dc.subject.keywordAuthor | rimary prevention | - |
dc.subject.keywordPlus | CARDIOVASCULAR-DISEASE | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | CHOLESTEROL | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | GUIDELINES | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.relation.journalResearchArea | Geriatrics & Gerontology | - |
dc.relation.journalWebOfScienceCategory | Geriatrics & Gerontology | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.